Peginterferon-α-2a/ribavirin/telaprevirDRESS syndrome: 3 case reports

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2012年 / 1415卷 / 1期
关键词：
Body Surface Area; Eosinophilia; Telaprevir; Atypical Lymphocyte; Erythematous Plaque;
D O I：
10.2165/00128415-201214150-00143
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：40 / 40
相关论文
共 34 条
  • [31] Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies
    Berger, K. L.
    Scherer, J.
    Ranga, M.
    Sha, N.
    Stern, J. O.
    Quinson, A. -M.
    Kukolj, G.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (10) : 6017 - 6025
  • [32] Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Kwo, Paul Y.
    Lawitz, Eric J.
    McCone, Jonathan
    Schiff, Eugene R.
    Vierling, John M.
    Pound, David
    Davis, Mitchell N.
    Galati, Joseph S.
    Gordon, Stuart C.
    Ravendhran, Natarajan
    Rossaro, Lorenzo
    Anderson, Frank H.
    Jacobson, Ira M.
    Rubin, Raymond
    Koury, Kenneth
    Pedicone, Lisa D.
    Brass, Clifford A.
    Chaudhri, Eirum
    Albrecht, Janice K.
    LANCET, 2010, 376 (9742) : 705 - 716
  • [33] Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
    Manns, Michael
    Marcellin, Patrick
    Poordad, Fred
    Affonso de Araujo, Evaldo Stanislau
    Buti, Maria
    Horsmans, Yves
    Janczewska, Ewa
    Villamil, Federico
    Scott, Jane
    Peeters, Monika
    Lenz, Oliver
    Ouwerkerk-Mahadevan, Sivi
    De La Rosa, Guy
    Kalmeijer, Ronald
    Sinha, Rekha
    Beumont-Mauviel, Maria
    LANCET, 2014, 384 (9941) : 414 - 426
  • [34] Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
    Jacobson, Ira M.
    Dore, Gregory J.
    Foster, Graham R.
    Fried, Michael W.
    Radu, Monica
    Rafalsky, Vladimir V.
    Moroz, Larysa
    Craxi, Antonio
    Peeters, Monika
    Lenz, Oliver
    Ouwerkerk-Mahadevan, Sivi
    De La Rosa, Guy
    Kalmeijer, Ronald
    Scott, Jane
    Sinha, Rekha
    Beumont-Mauviel, Maria
    LANCET, 2014, 384 (9941) : 403 - 413
1234